Microbiome-related R&D activities in the academic world are growing rapidly, especially in high-potential therapeutic fields (such as inflammatory diseases, cancer and neurodegenerative diseases).
Using our expertise and understanding of the microbiome, we are constantly looking for detecting new innovation and projects that have the potential to become innovative microbiome-based drug candidates.
We welcome understanding research teams working on the microbiome to engage with us.
LNC02 is a technical platform dedicated to developing expert know-how on Christensenella.
For this purpose, LNC is setting up a technical platform dedicated to studying the bacteria’s mechanisms of action, isolating new bacterial strains and targeting new therapeutic applications.